Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of moderate-to-severe plaque psoriasis for at least 6 months prior to enrollment;~* Candidate for phototherapy or systemic therapy;~* Premenopausal female participants must agree to abstain from heterosexual activity or use a medically approved method of contraception or use appropriate effective contraception as per local regulations or guidelines~* For the extension study: must have completed Part 3 of the base study~* For the extension study: must have achieved at least a PASI-50 response by the end of Part 3 of the base study~Exclusion Criteria:~* Non-plaque forms of psoriasis~* Presence or history of severe psoriatic arthritis and is well-controlled on current treatment regimen~* Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating~* Participant is expected to require topical therapy, phototherapy, or systemic therapy during the trial~* Presence of any infection or history of recurrent infection requiring treatment with systemic antibiotics~* Previous use of entanercept, tildrakizumab (MK-3222), or other interleukin-23 (IL-23)/T- helper cell 17 (Th-17) pathway inhibitors including p40, p19, and IL-17 antagonists~* Latex allergy or sensitivity~* Active or untreated latent tuberculosis (TB)~* For the extension study: women of child-bearing potential who are pregnant, intend to become pregnant within 6 months of completing the trial, or are breast feeding~* For the extension study: active or uncontrolled significant organ dysfunction or clinically significant laboratory abnormalities~* For the extension study: expected to require topical treatment, phototherapy, or systemic treatment during the extension study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tildrakizumab 200 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.
- Tildrakizumab 100 mg (Type: EXPERIMENTAL): Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
- Etanercept 50 mg (Type: ACTIVE_COMPARATOR): Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete